Espiard Stéphanie, Drougat Ludivine, Libé Rossella, Assié Guillaume, Perlemoine Karine, Guignat Laurence, Barrande Gaelle, Brucker-Davis Françoise, Doullay Françoise, Lopez Stephanie, Sonnet Emmanuel, Torremocha Florence, Pinsard Denis, Chabbert-Buffet Nathalie, Raffin-Sanson Marie-Laure, Groussin Lionel, Borson-Chazot Françoise, Coste Joël, Bertagna Xavier, Stratakis Constantine A, Beuschlein Felix, Ragazzon Bruno, Bertherat Jérôme
J Clin Endocrinol Metab. 2015 Jun;100(6):E926-35. doi: 10.1210/jc.2014-4204. Epub 2015 Apr 8.
Primary bilateral macronodular adrenal hyperplasia (PBMAH) is a rare cause of primary adrenal Cushing's syndrome (CS). ARMC5 germline mutations have been identified recently in PBMAH.
To determine the prevalence of ARMC5 mutations and analyze genotype-phenotype correlation in a large cohort of unrelated PBMAH patients with subclinical or clinical CS.
ARMC5 was sequenced in 98 unrelated PBMAH index cases. PBMAH was identified by bilateral adrenal nodular enlargement on computed tomography scan. The effect on apoptosis of ARMC5 missense mutants was tested in H295R and HeLa cells. Clinical and hormonal data were collected including midnight and urinary free cortisol levels, ACTH, androgens, renin/aldosterone ratio, cortisol after overnight dexamethasone suppression test, cortisol and 17-hydroxyprogesterone after ACTH 1-24 stimulation and illegitimate receptor responses. Computed tomography and histological reports were analyzed.
ARMC5-damaging mutations were identified in 24 patients (26%). The missense mutants and the p.F700del deletion were unable to induce apoptosis in both H295R and HeLa cell lines, unlike the wild-type gene. ARMC5-mutated patients showed an overt CS more frequently, compared to wild-type patients: lower ACTH, higher midnight plasma cortisol, urinary free cortisol, and cortisol after dexamethasone suppression test (P = .003, .019, .006, and <.001, respectively). Adrenals of patients with mutations were bigger and had a higher number of nodules (P = .001 and <.001, respectively).
ARMC5 germline mutations are common in PBMAH. Index cases of mutation carriers show a more severe hypercortisolism and larger adrenals. ARMC5 genotyping may help to identify clinical forms of PBMAH better and may also allow earlier diagnosis of this disease.
原发性双侧大结节性肾上腺增生(PBMAH)是原发性肾上腺库欣综合征(CS)的罕见病因。ARMC5种系突变最近在PBMAH中被发现。
确定ARMC5突变的患病率,并分析一大群无亲缘关系的亚临床或临床CS的PBMAH患者的基因型-表型相关性。
对98例无亲缘关系的PBMAH索引病例进行ARMC5测序。通过计算机断层扫描双侧肾上腺结节性增大来确定PBMAH。在H295R和HeLa细胞中测试ARMC5错义突变体对细胞凋亡的影响。收集临床和激素数据,包括午夜和尿游离皮质醇水平、促肾上腺皮质激素(ACTH)、雄激素、肾素/醛固酮比值、过夜地塞米松抑制试验后的皮质醇、ACTH 1-24刺激后的皮质醇和17-羟孕酮以及非法受体反应。分析计算机断层扫描和组织学报告。
在24例患者(26%)中发现了ARMC5有害突变。与野生型基因不同,错义突变体和p.F700del缺失在H295R和HeLa细胞系中均不能诱导细胞凋亡。与野生型患者相比,ARMC5突变患者更频繁地表现为显性CS:ACTH较低,午夜血浆皮质醇、尿游离皮质醇和地塞米松抑制试验后的皮质醇较高(P分别为0.003、0.019、0.006和<0.001)。突变患者的肾上腺更大,结节数量更多(P分别为0.001和<0.001)。
ARMC5种系突变在PBMAH中很常见。突变携带者的索引病例表现出更严重的皮质醇增多症和更大的肾上腺。ARMC5基因分型可能有助于更好地识别PBMAH的临床类型,也可能有助于该疾病的早期诊断。